Life sciences clauses

This subtopic includes a selection of definitions and standard commercial clauses for use in agreements in the life sciences sector.

For boilerplate commercial clauses and standard definitions which may be used in life sciences agreements, see: Boilerplate clauses—overview and Definitions—overview.

For a summary of the law, guidance and practice in relation to the execution of documents, along with standard execution clauses, see: Execution—overview.

Life sciences definitions

For examples of definitions which are frequently used in life sciences agreements, see Precedents:

  1. Applicable Laws and Medical Product Law definitions—life sciences

  2. Clinical trial laws definition—life sciences

  3. Derivatives definition—life sciences

  4. EU Notified Body and UK Approved Body definition—life sciences

  5. Exploit definition—life sciences

  6. Good Clinical Practice (GCP) definition—life sciences

  7. Good Laboratory Practice (GLP) definition—life sciences

  8. Governmental Entity definition—life sciences

  9. Industry Practice definition—life sciences

  10. Material definition—life sciences

  11. Principal investigator (PI) definition—life sciences

  12. Product definition—life sciences

  13. Progeny definition—life sciences

  14. Regulatory Documentation definition—life sciences

  15. Regulatory Approvals definition—life sciences

  16. Regulatory Authority definition—life sciences

Intellectual property

Intellectual

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

Life Sciences weekly highlights—16 October 2025

This week's edition of Life Sciences weekly highlights includes analysis by Freshfields LLP of recent highlights in the UK's medical devices regulatory framework and an MLex analysis indicating that the European Commission will issue guidelines on how the EU AI Act interacts with other EU laws such as the EU GDPR. Also included is news that MedTech Europe submitted recommendations to the European Commission’s call for evidence on the forthcoming European Innovation Act, the MHRA announced an expanded partnership with the US Food and Drug Administration (FDA) to accelerate innovation in medical technologies and AI and published guidance on new medical device registration fee planned to come into effect on 1 April 2026, and the European Notified Bodies industry group (Team-NB) and the Association of British HealthTech Industries (ABHI) responded to the Commission’s call for evidence on the targeted revision of the MDR and IVDR. Also included, is news that the MHRA has awarded the first three Innovation Passports under its revised Innovative Licensing and Access Pathway (ILAP), and together with NICE have opened early access to the aligned streamlined approvals pathway six months earlier than projected, EU industry bodies have criticised the European Commission’s upcoming study on costs for implementing quaternary-level treatment upgrades under the Urban Wastewater Treatment Directive (UWWTD) and, together with Cosmetics Europe, called for a data-driven, substance-based Extended Producer Responsibility (EPR) scheme, and the European Commission opened a public consultation on its proposed European Research Area Act, among other stories.

View Life Sciences by content type :

Popular documents